Page last updated: 2024-09-05

sb 216763 and Carcinoma, Anaplastic

sb 216763 has been researched along with Carcinoma, Anaplastic in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bar-Yehuda, S; Barer, F; Erlanger, A; Fishman, P; Madi, L; Ochaion, A; Ohana, G1

Other Studies

1 other study(ies) available for sb 216763 and Carcinoma, Anaplastic

ArticleYear
An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B.
    Oncogene, 2004, Apr-01, Volume: 23, Issue:14

    Topics: Adenosine; Animals; beta Catenin; Carcinoma; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Cyclin D1; Cytoskeletal Proteins; Down-Regulation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Growth Inhibitors; Humans; Indoles; Lithium; Maleimides; Mice; Mice, Nude; NF-kappa B; Proto-Oncogene Proteins c-myc; Purinergic P1 Receptor Agonists; Pyridines; Trans-Activators

2004